17607 Gold Plaza, Omaha, NE
Patient Portal

Welcome to the Urology Cancer Center

We are the region’s only cancer center dedicated solely to the treatment and research of prostate, kidney, bladder and testicular cancers. Our team of over 30 dedicated professionals have one mission: to provide each patient unsurpassed personalized cancer care accomplished through deep heartfelt compassion, extensive and comprehensible education, the most proficient cancer management, and an unparalleled focus on improving survival and quality of life.

Urology Cancer Center

We utilize a unique team approach: Dr. Luke and his Clinical Team, Research Coordinators, Treatment Nurses, Pharmacy, Scheduling and Financial staff work simultaneously during a patient’s visit to ensure delivery of the most accurate, personalized, efficient and expert care.

Learn More

Cancer Research

Dr. Luke's research team has access to potentially life-prolonging treatments years before they are available to the public. With our access to a growing pipeline of new drugs on clinical trials, UCC has the most available treatment options for urologic cancers compared to all other major centers.

Learn More

Patient Resources & Financial Assistance

We understand the financial burdens cancer may cause a patient and their family. We have highly trained and compassionate staff when it comes helping you choose the most appropriate insurance plans and obtaining assistance to minimize your out- of-pocket costs.

Learn More

Patient Testimonials

I’m 42 years old and was just diagnosed with Kidney Cancer. I was so scared. Dr Luke's office called me 3 days after my surgery to schedule an appointment, next thing I know Dr Luke is in my hospital room drawing out a description of what is going on. He spent a good hour and a half with my wife and me and that made me real comfortable. Then while I was in the hospital I had an MRI and they said they wouldn't have results till the next day. I no sooner got done and Dr Luke was up in my room giving me the good news about the MRI and spent about a half hour with us again. He explains everything step by step and makes you feel good that you chose him to help you with a very difficult time. I had my first visit to his office last week and let me tell you what a great experience that was, they really make this cancer thing a lot easier to deal with. So far we are confident that we made the right choice in a Doctor to fight this battle with us.

Kidney Cancer Patient
Read All Testimonials

Meet Our Team

Experts working together for your best outcome.

Luke Nordquist, M.D., F.A.C.P.

CEO, Urologic Medical Oncologist

Learn More

Kelly Hastings MSN, APRN

Nurse Practitioner

Learn More

Jenna DeSoe MSN, APRN

Nurse Practitioner

Learn More

Julie Willman MSN, APRN

Nurse Practitioner

Learn More

Sarah Meier MSN, APRN, OCN

Nurse Practitioner

Learn More

Click each logo to learn about our certifications.

QOPI Certification Program NCQA Certification

A Global Leader in Prostate Cancer Research

Cancer research is the only process available to discover and utilize new treatments for cancer patients. The Urology Center & GU Research Network is recognized by thought leaders, patients and pharmaceutical companies as a global leader in research.

Learn More

Recent News

FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer

May 21, 2020

Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.

View Article

FDA Approves First Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer

April 16, 2020

“This is the first approval specifically for patients with low-grade UTUC and provides an option for some patients who may otherwise require a nephroureterectomy,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research, in a statement.

View Article
All News